Literature DB >> 19893036

Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion.

Tracy Layton1, Cristel Stalens, Felizza Gunderson, Steve Goodison, Steve Silletti.   

Abstract

We have identified the nonreceptor tyrosine kinase syk as a marker of differentiation/tumor suppressor in pancreatic ductal adenocarcinoma (PDAC). Syk expression is lost in poorly differentiated PDAC cells in vitro and in situ, and stable reexpression of syk in endogenously syk-negative Panc1 (Panc1/syk) cells retarded their growth in vitro and in vivo and reduced anchorage-independent growth in vitro. Panc1/syk cells exhibited a more differentiated morphology and down-regulated cyclin D1, akt, and CD171, which are overexpressed by Panc1 cells. Loss of PDAC syk expression in culture is due to promoter methylation, and reversal of promoter methylation caused reexpression of syk and concomitant down-regulation of CD171. Moreover, suppression of syk expression in BxPC3 cells caused de novo CD171 expression, consistent with the reciprocal expression of syk and CD171 we observe in situ. Importantly, Panc1/syk cells demonstrated dramatically reduced invasion in vitro. Affymetrix analysis identified statistically significant regulation of >2000 gene products by syk in Panc1 cells. Of these, matrix metalloproteinase-2 (MMP2) and tissue inhibitor of metalloproteinase-2 were down-regulated, suggesting that the MMP2 axis might mediate Panc1/mock invasion. Accordingly, MMP2 inhibition suppressed the in vitro invasion of Panc1/mock cells without effect on Panc1/syk cells. This study demonstrates a prominent role for syk in regulating the differentiation state and invasive phenotype of PDAC cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893036      PMCID: PMC2789622          DOI: 10.2353/ajpath.2009.090543

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  [Association between hypermethylation of Syk gene and clinicopathological characteristics in colorectal cancer patients].

Authors:  Zu-li Yang; Lei Wang; Liang Kang; Jun-sheng Peng; Jun Xiang; Mei-jin Huang; Jian-ping Wang
Journal:  Zhonghua Wei Chang Wai Ke Za Zhi       Date:  2008-09

2.  The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells.

Authors:  P J Coopman; M T Do; M Barth; E T Bowden; A J Hayes; E Basyuk; J K Blancato; P R Vezza; S W McLeskey; P H Mangeat; S C Mueller
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

3.  Factors influencing survival after resection for periampullary neoplasms.

Authors:  M Bouvet; R A Gamagami; E A Gilpin; O Romeo; A Sasson; D W Easter; A R Moossa
Journal:  Am J Surg       Date:  2000-07       Impact factor: 2.565

Review 4.  Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma.

Authors:  D Antonello; S Gobbo; V Corbo; B Sipos; N R Lemoine; A Scarpa
Journal:  Pancreatology       Date:  2008-12-12       Impact factor: 3.996

5.  Additional MDA-MB-231 breast cancer cell matrix metalloproteinases promote invasiveness.

Authors:  Luca Hegedüs; Hyojin Cho; Xian Xie; George L Eliceiri
Journal:  J Cell Physiol       Date:  2008-08       Impact factor: 6.384

Review 6.  L1-CAM in cancerous tissues.

Authors:  Nancy Gavert; Amir Ben-Shmuel; Shani Raveh; Avri Ben-Ze'ev
Journal:  Expert Opin Biol Ther       Date:  2008-11       Impact factor: 4.388

7.  Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells.

Authors:  Xiaoying Zhang; Ulka Shrikhande; Bethany M Alicie; Qing Zhou; Robert L Geahlen
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

8.  EGF promotes invasion by PANC-1 cells through Rac1/ROS-dependent secretion and activation of MMP-2.

Authors:  Marcelo G Binker; Andres A Binker-Cosen; Daniel Richards; Brenda Oliver; Laura I Cosen-Binker
Journal:  Biochem Biophys Res Commun       Date:  2008-12-29       Impact factor: 3.575

9.  Disruption of matrix metalloproteinase 2 binding to integrin alpha vbeta 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo.

Authors:  S Silletti; T Kessler; J Goldberg; D L Boger; D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

10.  The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.

Authors:  Q Zhou; R L Geahlen
Journal:  Oncogene       Date:  2009-01-19       Impact factor: 9.867

View more
  23 in total

Review 1.  Pathways of oncogene-induced senescence in human melanocytic cells.

Authors:  Rajat Bansal; Mikhail A Nikiforov
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

2.  Syk interacts with and phosphorylates nucleolin to stabilize Bcl-x(L) mRNA and promote cell survival.

Authors:  Wen-Horng Wang; Michael O Childress; Robert L Geahlen
Journal:  Mol Cell Biol       Date:  2014-08-04       Impact factor: 4.272

3.  Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.

Authors:  So-Hyun Shin; Kwang Ho Lee; Baek-Hee Kim; Sun Lee; Hwan Seok Lee; Ja-June Jang; Gyeong Hoon Kang
Journal:  Lab Invest       Date:  2014-10-13       Impact factor: 5.662

4.  Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.

Authors:  Hui Peng; Jun Huang; Ying Hu; Yisheng Wei; Huanliang Liu; Meijin Huang; Lei Wang; Jianping Wang
Journal:  Cell Oncol (Dordr)       Date:  2015-04-29       Impact factor: 6.730

Review 5.  Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

Authors:  Mariya O Krisenko; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2014-11-04

6.  Comparative Analysis of the Transcriptome and Proteome during Mouse Placental Development.

Authors:  Majd Abdulghani; Gaoyuan Song; Haninder Kaur; Justin W Walley; Geetu Tuteja
Journal:  J Proteome Res       Date:  2019-04-15       Impact factor: 4.466

7.  Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.

Authors:  Jian Hong; Yunfei Yuan; Jianping Wang; Yadi Liao; Ruhai Zou; Chuanlong Zhu; Binkui Li; Yi Liang; Pinzhu Huang; Zongwei Wang; Wenyu Lin; Yixin Zeng; Jia Le Dai; Raymond T Chung
Journal:  Cancer Res       Date:  2014-01-29       Impact factor: 12.701

8.  Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.

Authors:  Shweta Joshi; Donald L Durden; Kevin X Liu; Muamera Zulcic; Alok R Singh; Dylan Skola; Christopher K Glass; P Dominick Sanders; Andrew B Sharabi; Timothy V Pham; Pablo Tamayo; Daniel Shiang; Huy Q Dinh; Catherine C Hedrick; Guillermo A Morales; Joseph R Garlich
Journal:  Mol Cancer Ther       Date:  2020-01-23       Impact factor: 6.261

Review 9.  Getting Syk: spleen tyrosine kinase as a therapeutic target.

Authors:  Robert L Geahlen
Journal:  Trends Pharmacol Sci       Date:  2014-06-26       Impact factor: 14.819

10.  CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.

Authors:  Jian Hong; Kaishun Hu; Yunfei Yuan; Yi Sang; Qiangui Bu; Guihua Chen; Longjun Yang; Binkui Li; Pinzhu Huang; Dongtai Chen; Yi Liang; Ruhua Zhang; Jingxuan Pan; Yi-Xin Zeng; Tiebang Kang
Journal:  J Clin Invest       Date:  2012-05-15       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.